Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. SXTC
SXTC logo

SXTC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.235
Open
2.080
VWAP
2.16
Vol
21.63K
Mkt Cap
1.99M
Low
2.080
Amount
46.75K
EV/EBITDA(TTM)
--
Total Shares
957.96K
EV
-18.12M
EV/OCF(TTM)
--
P/S(TTM)
0.53
China SXT Pharmaceuticals Inc is a holding company principally engaged in the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). TCMP is a type of Chinese Traditional Medicine (TCM) products. The Company sells three types of TCMP products: Advanced TCMP, Fine TCMP and Regular TCMP. The Company sells its products under the brand Suxuantang. The Company mainly operates its businesses in the domestic market.
Show More

Events Timeline

(ET)
2026-01-15
09:20:00
China SXT Pharmaceuticals Launches AI Initiative to Enhance TCM Supply Chain
select
2026-01-09 (ET)
2026-01-09
15:00:00
China SXT Pharmaceuticals Enters Agreement to Sell 66.67M Shares
select
2026-01-08 (ET)
2026-01-08
16:30:00
Major Averages Mixed as Oil Prices Surge Nearly 4%
select
2026-01-08
12:00:00
Major Averages Mixed Near Noon as Investors Reassess 2026 Optimism
select
2026-01-08
09:30:00
China SXT Pharmaceuticals Launches Strategic AI Insights Initiative
select
2025-03-17 (ET)
2025-03-17
08:33:45
China SXT Pharmaceuticals regains compliance with Nasdaq
select
2024-10-07 (ET)
2024-10-07
16:20:38
China SXT Pharmaceuticals receives noncompliance notification from Nasdaq
select

News

Benzinga
9.5
02-02Benzinga
DarkIris Inc Reports 27.3% Revenue Growth, Shares Surge
  • Significant Revenue Growth: DarkIris Inc reported a year-over-year revenue increase of 27.3% for FY25, reaching $10.08 million compared to $7.92 million in FY24, indicating strong market performance and growth potential.
  • Stock Price Surge: Following the positive earnings report, DarkIris shares jumped 104.2% in pre-market trading to $0.68, reflecting investor optimism about the company's future prospects.
  • Positive Market Reaction: The release of this earnings report has significantly increased market attention on DarkIris, enhancing investor confidence in its continued growth and potentially attracting more capital inflow.
  • Optimistic Industry Outlook: The robust performance of DarkIris not only strengthens its market position but may also provide more opportunities for future financing and expansion plans, further solidifying its competitive edge in the industry.
stocktwits
2.0
01-30stocktwits
China SXT Pharmaceuticals Announces 1-for-150 Reverse Stock Split to Boost Share Price
  • Reverse Stock Split: China SXT Pharmaceuticals announced a 1-for-150 reverse stock split effective February 3, 2026, which will reduce outstanding shares from approximately 143.7 million to 958,000, aimed at boosting the share price to comply with Nasdaq's $1 minimum bid requirement.
  • Increased Selling Pressure: Since the beginning of the year, SXTC shares have declined over 75%, and following the reverse split announcement, the stock plummeted nearly 30% on Friday, currently trading around $0.3, indicating market concerns about the company's future.
  • Impact of Financing Deal: On January 9, SXTC signed a deal with a single investor to sell about 66.7 million Class A shares at $0.15 each, causing the stock to crash 87%, reflecting strong market reactions to the company's financing strategy.
  • AI Initiative Launch: The company recently launched an AI initiative to modernize the traditional Chinese medicine raw-material supply chain, exploring AI tools for cultivation monitoring, authenticity checks, quality grading, and demand forecasting to enhance traceability and planning efficiency.
seekingalpha
8.5
01-30seekingalpha
China SXT Pharmaceuticals Announces 1-for-150 Share Consolidation
  • Capital Structure Adjustment: China SXT Pharmaceuticals announced a 1-for-150 share consolidation effective February 3, 2026, reducing its Class A shares from approximately 143.7 million to about 957,960, which aims to optimize its capital structure and enhance per-share value.
  • Exchange Change: Post-consolidation, the Class A shares will trade on Nasdaq under the new symbol “SXTC,” with a new CUSIP number coming into effect, which is expected to improve market visibility and liquidity.
  • Rights Adjustment: All outstanding options, warrants, and other rights to purchase Class A shares will be adjusted proportionately, ensuring that shareholder rights are preserved, thereby maintaining investor confidence.
  • Market Reaction: Following the announcement of the consolidation, SXTC's stock price fell by 21.4% to $0.0393, reflecting a cautious market sentiment regarding the decision, which may impact the company's future financing capabilities and investor sentiment.
Newsfilter
8.5
01-30Newsfilter
China SXT Pharmaceuticals Announces Share Consolidation
  • Share Consolidation Ratio: China SXT Pharmaceuticals announced a 1-for-150 share consolidation effective February 3, 2026, which will reduce the outstanding shares to approximately 957,960, significantly impacting shareholder equity and market liquidity.
  • Exchange Continuity: Post-consolidation, the ordinary shares will continue trading on Nasdaq under the symbol "SXTC" with a new CUSIP number G2161P165, ensuring seamless trading for investors after the consolidation.
  • Shareholder Rights Adjustment: All outstanding stock options, warrants, and other rights to purchase shares will be proportionately adjusted to reflect the consolidation, safeguarding shareholder interests and maintaining governance transparency.
  • Investor Communication: The company advises shareholders to contact their banks, brokers, or nominees for details regarding the consolidation, ensuring timely and accurate information dissemination to bolster investor confidence and reduce market uncertainty.
Benzinga
2.0
01-27Benzinga
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
  • Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
  • Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
  • Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
  • Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.
Benzinga
8.5
01-14Benzinga
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
  • Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
  • Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
  • Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
  • Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.

Valuation Metrics

The current forward P/E ratio for China SXT Pharmaceuticals Inc (SXTC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess China SXT Pharmaceuticals Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Help me find stocks that are under 2.00
Intellectia · 531 candidates
Region: USPrice: <= $2.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
APLT logo
APLT
Applied Therapeutics Inc
14.24M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.42M
ZJYL logo
ZJYL
Jin Medical International Ltd
25.25M
CENN logo
CENN
Cenntro Inc (The Corporation)
13.35M
BURU logo
BURU
NUBURU Inc
76.36M
UGRO logo
UGRO
urban-gro Inc
3.10M
Stocks under 1 dollar
Intellectia · 291 candidates
Price: $0.00 - $1.00List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
MTEN logo
MTEN
Mingteng International Corp Inc
4.13M
ATPC logo
ATPC
Agape ATP Corp
3.93M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
10.96M
APLT logo
APLT
Applied Therapeutics Inc
15.14M
MKDW logo
MKDW
MKDWELL Tech Inc
12.07M
PTLE logo
PTLE
PTL Ltd
11.70M
Stocks under 1$
Intellectia · 374 candidates
Price: <= $1.00
Ticker
Name
Market Cap$
top bottom
MTEN logo
MTEN
Mingteng International Corp Inc
4.13M
ATPC logo
ATPC
Agape ATP Corp
3.93M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
10.96M
APLT logo
APLT
Applied Therapeutics Inc
15.14M
MKDW logo
MKDW
MKDWELL Tech Inc
12.07M
PFSA logo
PFSA
Profusa Inc
9.85M
stock under 5$ bulish for tomorrow
Intellectia · 447 candidates
Price: <= $5.00
Ticker
Name
Market Cap$
top bottom
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
ZJYL logo
ZJYL
Jin Medical International Ltd
19.82M
WCT logo
WCT
Wellchange Holdings Co Ltd
22.89M
PASW logo
PASW
Ping An Biomedical Co Ltd
3.72M
JOB logo
JOB
GEE Group Inc
23.64M
UGRO logo
UGRO
urban-gro Inc
3.53M
best penny stock under 10 dollars today
Intellectia · 1578 candidates
Price: <= $10.00Market Cap Category: micro, nano
Ticker
Name
Market Cap$
top bottom
MTEN logo
MTEN
Mingteng International Corp Inc
5.55M
ATPC logo
ATPC
Agape ATP Corp
4.10M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
CCTG logo
CCTG
CCSC Technology International Holdings Ltd
3.84M
APLT logo
APLT
Applied Therapeutics Inc
14.63M
PTLE logo
PTLE
PTL Ltd
10.48M
stocks under $0.10 with high volume
Intellectia · 4 candidates
Price: <= $0.10Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MTEN logo
MTEN
Mingteng International Corp Inc
5.55M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
CCTG logo
CCTG
CCSC Technology International Holdings Ltd
3.84M
ATPC logo
ATPC
Agape ATP Corp
4.10M
stocks under $1 that will be bullish today
Intellectia · 96 candidates
Price: <= $1.00
Ticker
Name
Market Cap$
top bottom
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
SAFX logo
SAFX
XCF Global Inc
28.75M
MKDW logo
MKDW
MKDWELL Tech Inc
14.59M
SRXH logo
SRXH
Srx Health Solutions Inc
11.89M
ADIL logo
ADIL
Adial Pharmaceuticals Inc
6.04M
GRI logo
GRI
GRI Bio Inc
2.26M
stocks under $0.50 with an rsi under 20
Intellectia · 33 candidates
Price: <= $0.50Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
MTEN logo
MTEN
Mingteng International Corp Inc
5.55M
ATPC logo
ATPC
Agape ATP Corp
4.10M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
CCTG logo
CCTG
CCSC Technology International Holdings Ltd
3.84M
APLT logo
APLT
Applied Therapeutics Inc
14.63M
ZJYL logo
ZJYL
Jin Medical International Ltd
19.82M
stocks under $1 with an rsi under 20
Intellectia · 53 candidates
Price: <= $1.00Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
AIIO logo
AIIO
Robo.ai Inc
89.22M
PSTV logo
PSTV
Plus Therapeutics Inc
52.05M
HURA logo
HURA
TuHURA Biosciences Inc
41.71M
XLO logo
XLO
Xilio Therapeutics Inc
40.33M
POM logo
POM
PomDoctor Ltd
35.21M
OTLK logo
OTLK
Outlook Therapeutics Inc
32.44M
200 usd to start now wats my first step
Intellectia · 3944 candidates
Region: USPrice: $0.00 - $200.00
Ticker
Name
Market Cap$
top bottom
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
11.70M
APLT logo
APLT
Applied Therapeutics Inc
14.63M
ZJYL logo
ZJYL
Jin Medical International Ltd
19.82M
CENN logo
CENN
Cenntro Inc (The Corporation)
12.95M
BURU logo
BURU
NUBURU Inc
77.15M
WORX logo
WORX
Scworx Corp
2.85M

Whales Holding SXTC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is China SXT Pharmaceuticals Inc (SXTC) stock price today?

The current price of SXTC is 2.17 USD — it has increased 4.33

What is China SXT Pharmaceuticals Inc (SXTC)'s business?

China SXT Pharmaceuticals Inc is a holding company principally engaged in the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). TCMP is a type of Chinese Traditional Medicine (TCM) products. The Company sells three types of TCMP products: Advanced TCMP, Fine TCMP and Regular TCMP. The Company sells its products under the brand Suxuantang. The Company mainly operates its businesses in the domestic market.

What is the price predicton of SXTC Stock?

Wall Street analysts forecast SXTC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is China SXT Pharmaceuticals Inc (SXTC)'s revenue for the last quarter?

China SXT Pharmaceuticals Inc revenue for the last quarter amounts to NaN USD, decreased

What is China SXT Pharmaceuticals Inc (SXTC)'s earnings per share (EPS) for the last quarter?

China SXT Pharmaceuticals Inc. EPS for the last quarter amounts to USD, decreased

How many employees does China SXT Pharmaceuticals Inc (SXTC). have?

China SXT Pharmaceuticals Inc (SXTC) has 75 emplpoyees as of March 11 2026.

What is China SXT Pharmaceuticals Inc (SXTC) market cap?

Today SXTC has the market capitalization of 1.99M USD.